Clinical trial · no report yet · Phase 3
TREAT ctDNA
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- NCT05512364 ↗
- Recruiting
- European Organisation for Research and Treatment of Cancer - EORTC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 14 | |
| YouTube | 10 | |
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer
- Interventions
- Elacestrant; Tamoxifen; Letrozole 2.5mg; Anastrozole 1mg; Exemestane 25 MG
- Arms
- Experimental arm · Experimental
- Control arm · Active comparator
- Enrollment
- 220 (estimated)
- Primary outcomes
- Distant metastasis free survival (DMFS)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC with Menarini Group, Natera, Inc., Borstkanker Onderzoek Groep, Cancer Trials Ireland, SOLTI Breast Cancer Research Group, ETOP IBCSG Partners Foundation, SUCCESS, Hellenic Cooperative Oncology Group, Hellenic Oncology Research Group, Swedish Breast Cancer Group
- Start
- Dec 15, 2023
- Primary completion
- Nov 1, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT05512364 · updated Oct 7, 2026